S.J. Res. 198 (119th)Bill Overview

Disapprove CMS WISeR Prior Authorization Rule

CRA DisapprovalHealth|Health
Sponsor
Cosponsors
Support
Democratic
Introduced
Jun 24, 2026
Discussions
Bill Text
Current stageCommittee

Placed on Senate Legislative Calendar under General Orders. Calendar No. 447.

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief
CRA DisapprovalWhat this resolution actually does

This resolution uses the Congressional Review Act to nullify a federal agency rule. If Congress approves the resolution and the President signs it (or a veto is overridden), the named rule is treated as having no force or effect. The Act also prevents the agency from issuing a substantially similar rule in the future unless Congress passes new law authorizing it.

Rule targeted

The rule titled "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model."

Issuing agency

Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS)

Passage rules

Under the Congressional Review Act, this disapproval resolution is subject to expedited procedures in the Senate that limit debate and prevent a filibuster, so it can pass there with a simple majority; it must also pass the House and be presented to the President to take effect.

This joint resolution under the Congressional Review Act would disapprove and nullify a Centers for Medicare & Medicaid Services rule titled “Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model,” removing that rule from effect.

Passage30/100

Narrow regulatory target raises feasibility in one chamber, but needing approval in both and possible executive opposition, plus stakeholder lobbying, reduce overall odds.

CredibilityAligned

Relative to its intended legislative type, this bill is a narrowly targeted Congressional Review Act disapproval that is clear about its legal effect and integrates explicitly with the CRA framework, but it provides minimal ancillary detail (fiscal, transitional, or oversight) beyond what the governing statute supplies.

Contention35/100

Progressives emphasize protecting patient access and avoiding delays

02 · What it does

Who stands to gain, and who may push back.

Likely benefits vs burdens50% / 50%
Likely helpedLikely burdened

These are examples from the analysis, not a ranked list of the most-affected groups.

Likely helped
  • Potential benefitPrevents implementation of prior authorization requirements that would have added administrative burden to clinicians a…
  • Potential benefitReduces potential for delayed patient access to certain Medicare-covered services due to prior authorization processes.
  • Potential benefitAvoids compliance costs for providers and insurers tied to new authorization systems and IT integration.
Likely burdened
  • Potential burdenBlocks CMS efforts to curb wasteful or inappropriate services through utilization management.
  • Potential burdenMay maintain higher Medicare program spending that the prior authorization rule intended to reduce.
  • Potential burdenKeeps status quo that could allow continued provision of low-value or unnecessary services.
03 · Why people split

Why the argument around this bill splits.

Progressives emphasize protecting patient access and avoiding delays
Progressive85%

Likely supportive of disapproval because prior authorization can delay care and add administrative burdens.

Support would be tempered by interest in reducing waste and ensuring Medicare integrity.

Leans supportive
Centrist50%

Mixed view: appreciates goals to curb waste but worries about access harms from blunt prior-authorization rules.

Prefers fixing or phasing implementation rather than outright nullification.

Split reaction
Conservative90%

Generally supportive of disapproval as a check on administrative overreach and regulatory burden.

Views CRA use as appropriate to block an intrusive federal prior-authorization regime.

Leans supportive
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Still ahead

President

Still ahead

Law

Still ahead

Passage likelihood30/100

Narrow regulatory target raises feasibility in one chamber, but needing approval in both and possible executive opposition, plus stakeholder lobbying, reduce overall odds.

Scope and complexity
24%
Scopenarrow
24%
Complexitylow
Why this could stall
  • Absent official cost or budgetary estimate
  • Unknown positions of major provider and beneficiary groups
05 · Recent votes

Recent votes on the bill.

06 · Go deeper

Go deeper than the headline read.

Included on this page

Progressives emphasize protecting patient access and avoiding delays

Narrow regulatory target raises feasibility in one chamber, but needing approval in both and possible executive opposition, plus stakeholde…

Unlocked analysis

Relative to its intended legislative type, this bill is a narrowly targeted Congressional Review Act disapproval that is clear about its legal effect and integrates explicitly with the CRA framework, but it provides min…

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis